Every 8-K that ABPRO HOLDINGS INC WTS (ABPWW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABPWW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABPWW filings page.
Abpro Holdings, Inc. (ABPO) announced that Chief Executive Officer Miles Suk voluntarily resigned from the CEO role effective August 19, 2026, while remaining on the Board of Directors. The Board appointed M. Fatih Karatas, 47, as Interim Chief Executive Officer, effective August 25, 2026. The company states Mr. Suk’s resignation was not due to any disagreement regarding operations, policies, or practices.
Mr. Karatas brings over 20 years of experience in global finance and investment management, including leadership roles at AIS Advisors, SAASPASS, QInvest, and UBS AG overseeing portfolios exceeding $130 billion. He will serve as interim CEO without compensation for three months, after which a compensation arrangement may be considered. In connection with his resignation as CEO, Mr. Suk’s consulting agreement was terminated, and he is entitled to continued pro-rata payments of his $300,000 annual consulting fee for 60 days, totaling approximately $50,000.
Abpro Holdings, Inc. received notice from the Nasdaq Listing and Hearing Review Council that it reaffirmed a prior decision to delist the company’s securities from Nasdaq. The Council cited Abpro’s failure to meet the minimum equity standard under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline set in a November 10, 2025 panel decision.
Abpro expects Nasdaq to file a Form 25 to delist and deregister its securities under Section 12(b) of the Exchange Act. The company expects its common stock and public warrants to continue quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW,” but warns holders about potentially limited information availability, reduced transparency and liquidity, and greater trading volatility.
Abpro Holdings, Inc. reported that Nasdaq’s Hearings Panel has decided to delist its common stock and public warrants because the company did not meet the minimum equity requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026. Trading on Nasdaq is scheduled to be suspended at the open on February 23, 2026.
The company has 15 days from February 18, 2026 to request a review by the Nasdaq Listing and Hearing Review Council and expects to appeal. If no appeal is pursued or successful, Nasdaq is expected to file a Form 25 to delist and deregister the securities under Section 12(b).
After Nasdaq trading is suspended, Abpro expects its common stock and public warrants to be eligible for quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW.” The company warns investors that OTC Pink trading may involve reduced information, lower liquidity, and greater price volatility, and it cannot assure that any broker-dealer will make a market in its securities.
Abpro Holdings, Inc. reported that Nasdaq has notified the company it is no longer in compliance with several board and committee independence listing rules following the recent resignations of two independent directors, creating additional bases for potential delisting from The Nasdaq Capital Market.
Nasdaq cited noncompliance with rules requiring a majority-independent board, a three-member independent audit committee, and a two-member independent compensation committee. Abpro must present its views to a Nasdaq Hearings Panel by February 12, 2026, and has a cure period for the compensation committee extending to certain future shareholder meeting dates.
On February 9, 2026, Abpro appointed M. Fatih Karatas and Mary Gunn as Class II directors and to the audit, compensation, and nominating and corporate governance committees, aiming to address the independence and composition deficiencies. The company notes there is no immediate impact on the listing of its common stock or warrants, but there is no assurance it will regain full compliance or that the Panel will grant continued listing.
Abpro Holdings, Inc. reported that two members of its Board of Directors, Anthony D. Eisenberg and Sooyoung Lee, have resigned from the board and all related committees. Both resignations were effective in late January 2026 and were explicitly stated as not arising from any disagreement with the company, its board, or its management on operations, policies, or practices.
Following these departures, the Board has begun a process to identify and appoint new qualified independent directors to fill the vacancies and to meet applicable Nasdaq Stock Market requirements within the time periods allowed by the Nasdaq Listing Rules.
Abpro Holdings, Inc. entered into an unsecured $147,000 loan agreement with its Chief Executive Officer and Chairman, Miles J.W. Suk, to pay the premium for its directors’ and officers’ liability insurance. The CEO will pay the insurer or broker directly, and the funds may be used only for that insurance cost.
The loan runs for nine months and can be repaid early without penalty. No interest is charged for the first three months after funding; after that, the outstanding principal bears interest at a variable rate equal to three-month Term SOFR plus 2.0% per year, with interest due at maturity or earlier repayment. The loan is unsecured and not guaranteed by any third party.
On January 16, 2026, director Ian McDonald resigned from Abpro’s board and all board committees, with the company stating his resignation was not due to any disagreement over operations, policies, or practices. The board appointed Dr. Byung-Hak Yoon as a Class I director to fill the vacancy, with a term ending at the 2028 annual meeting, and named him to the Audit, Compensation, and Nominating and Corporate Governance Committees. Dr. Yoon, age 51, brings extensive leadership experience in biotechnology and medical companies and will receive the company’s standard compensation for independent directors.